Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 7.703 billion, representing a year-on-year increase of 20.07%[19] - The net profit attributable to shareholders for the same period was CNY 182.71 million, up 49.73% compared to the previous year[19] - The net cash flow from operating activities increased significantly by 221.76%, amounting to CNY 531.46 million[19] - The basic earnings per share rose to CNY 0.07, reflecting a growth of 40.00% year-on-year[20] - The net profit attributable to shareholders reached 183 million RMB, representing a year-on-year increase of 49.73%[22] - The pharmaceutical commercial segment achieved revenue of CNY 5,275.22 million, a year-on-year increase of 14.57%, and net profit attributable to shareholders of CNY 153.34 million, up 44.81%[53] - The gross margin for the pharmaceutical commercial segment was 9.37%, an increase of 0.33% year-on-year[53] - The total comprehensive income for the first half of 2023 was CNY 220,059,515.47, an increase of 51.06% from CNY 145,592,026.94 in the previous year[153] Assets and Liabilities - The company’s total assets at the end of the reporting period were CNY 13.735 billion, a 2.22% increase from the end of the previous year[19] - The net assets attributable to shareholders increased by 4.28% to CNY 4.516 billion[19] - The company's total liabilities were CNY 8,559,656,817.08, slightly up from CNY 8,484,927,244.36, marking an increase of about 0.9%[142] - The company's short-term borrowings decreased by 7.82% to CNY 1,781,727,447.21, reflecting a strategic reduction in financing scale[65] - The total equity of the company was CNY 5,174,012,147.23, slightly down from CNY 5,051,053,669.26, reflecting a decrease of about 2.4%[142] Market and Product Development - The pharmaceutical commercial sector saw growth in both wholesale and retail businesses, driven by an expanded product range and enhanced sales management[21] - The company has strengthened its collaboration with medical institutions, increasing the sales proportion of high-quality customers[21] - The introduction of DTP products and improvement in pharmacy service capabilities contributed to the growth of specialized pharmacy sales[21] - The pharmaceutical industrial segment achieved breakthroughs in respiratory and gastrointestinal products, contributing to overall sales growth[22] - The company holds 1,802 drug approvals and 100 health product approvals, focusing on major therapeutic areas such as infection, chronic diseases, and respiratory health[29] - The company is focusing on the development of key products in the anti-infection and respiratory medication sectors, aiming to enhance brand influence and market competitiveness[56] - The company plans to focus on the health product sector, with multiple health products expected to be launched in the second half of the year[59] Operational Efficiency and Strategy - The company actively optimized its product mix and supply chain management, improving operational efficiency and gross margin[22] - The company implemented a clear product channel strategy, enhancing product penetration and network coverage across various channels[22] - The company is transitioning to an operational control model, implementing a comprehensive budget management system to optimize resource allocation and enhance strategic execution[41] - The company has established a comprehensive product lifecycle management system to optimize procurement, production, and inspection cycles, effectively shortening supply cycles[48] - The company has implemented lean production principles to improve product quality and control production costs, achieving a 46% reduction in process nodes through procurement optimization[48] Research and Development - The company is focused on R&D in chemical synthesis, modern traditional Chinese medicine, and biotechnology, supported by six national high-tech enterprises and various provincial research centers[37] - The company is actively developing over 20 products in research, focusing on therapeutic areas such as digestion and chronic diseases, with several products undergoing consistency evaluation[46] - The company aims to enhance product competitiveness by leveraging consumer demand and launching new products in response to market opportunities[44] Environmental and Social Responsibility - The company has established a quality assurance system aligned with international standards, ensuring product quality exceeds national legal requirements[38] - The company has implemented a carbon reduction strategy, including a pilot photovoltaic power generation project and measures to optimize production efficiency, resulting in reduced production costs and energy consumption[104] - The company donated materials worth CNY 1.4068 million through its charity foundation, benefiting nearly 98,000 people during the reporting period[105] - The company has established a comprehensive environmental protection responsibility system and has set annual environmental management goals and indicators, which are regularly assessed[101] Shareholder and Capital Management - The company’s total share capital decreased from 2,525,877,076 shares to 2,523,478,076 shares due to the repurchase and cancellation of 2,399,000 restricted shares[117] - The company reported a total of 1,327,000 newly unrestricted shares during the reporting period[123] - The company continues to monitor shareholder dynamics and the impact of stock repurchase on overall shareholder value[129] - The total equity attributable to the parent company reached 4,951,053.6 million, with a significant increase compared to the previous period[164] Future Outlook - The company plans to expand its market presence and invest in new product development to sustain growth in the upcoming quarters[1] - Future guidance indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion efforts[166] - The company is exploring potential mergers and acquisitions to enhance its market position and operational capabilities[166]

哈药集团股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 哈药集团股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开了第九届董事会第三十八次会议及第九届监事会第二十次会 议，审议通过了《2023 年 1-6 月计提资产减值准备的议案》，现将具 体情况公告如下： 证券代码:600664 证券简称:哈药股份 编号:临 2023-047 公司至少于每年年度终了，对固定资产逐项进行检查，如果发现 由于市价持续下跌，或技术陈旧、损坏、长期闲置等原因导致其可收 回金额低于其账面价值的，对其可收回金额低于其账面价值的差额计 提固定资产减值准备。按单项固定资产计提减值准备，并计入当期损 益。 2023 年 1-6 月固定资产减值准备母公司无计提，因资产处置或 报废原因减少 3.62 万元，期末余额为 10,030.41 万元；合并无计提， 因资产处置或报废原因减少 9.78 万元，期末余额为 13,493.20 万元。 一、计提资产减值准备的概述 为真实、公允地反映公司的财务状况和经 ...

公司 2023 年 1-6 月合并财务报表中计提的资产减值准备情况如 下：坏账准备合并计提 2,241.41 万元，存货跌价准备合并计提 2,250.82 万元，本期合并计提 4,492.23 万元，转回 1,817.98 万元, 转销 2,168.71 万元，影响公司本期利润总额 505.54 万元。 具 体 内 容 详 见 公 司 同 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《哈药集团股份有限公司关于计提资产减 值准备的公告》。 一、2023 年半年度报告全文及摘要（同意 9 票，反对 0 票，弃 权 0 票） 具 体 内 容 详 见 公 司 同 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的 2023 年半年度报告全文及摘要。 二、2023 年 1-6 月计提资产减值准备的议案（同意 9 票，反对 0 票，弃权 0 票） 公司依据《企业会计准则》以及所在行业和公司资产的实际情况 计提资产减值准备，本次计提资产减值准备依据充分，真实地反映公 司财务状况和对公司经营成果的影响，公司董事会同意计提本次资产 减值准备。 证券代码:60 ...

公司本次计提资产减值准备遵照并符合《企业会计准则》、《公司 资产减值准备提取和核销规则》和公司相关会计政策的规定，本次计 提资产减值准备基于会计谨慎性原则，计提依据充分，并能真实地反 映公司资产价值及财务状况，有助于为投资者提供更可靠的会计信息。 因此，同意公司计提该项资产减值准备。 哈药集团股份有限公司独立董事： 潘广成、卢卫红、娄爱东、李兆华 二〇二三年八月二十四日 哈药集团股份有限公司独立董事 关于公司九届三十八次董事会相关事项的独立意见 根据《上市公司独立董事规则》、《上市公司治理准则》、《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规 和规范性文件及《公司章程》的有关规定，我们作为哈药集团股份有 限公司（以下简称"公司"）的独立董事，基于客观、独立的立场、 审慎负责的态度对公司九届三十八次董事会审议的《2023 年 1-6 月 计提资产减值准备的议案》发表如下独立意见： 1 ...

监事会对公司编制的 2023 年半年度报告提出如下审核意见： 1、半年报的编制和审议程序符合法律、法规、《公司章程》和公司内部 管理制度的规定； 2、半年报的内容符合中国证监会和上海证券交易所的各项规定，所包含 的信息能从各个方面真实地反映公司 2023 年上半年的经营和财务状况； 3、在本意见提出前，未发现参与半年报编制和审议的人员有违反保密规 定的行为。 证券代码:600664 证券简称:哈药股份 编号:临2023-046 哈药集团股份有限公司 九届二十次监事会决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第九届监事会第二十次会议 以书面方式发出通知，于 2023 年 8 月 24 日以通讯表决方式召开,会议应到监 事 3 人，实到监事 3 人，会议召开符合《公司法》和《公司章程》的有关规 定。会议由监事会主席边科先生主持，审议通过了如下议案： 一、《2023 年半年度报告全文及摘要》（同意 3 票，反对 0 票，弃权 0 票） 1 哈药集团股份有限公司监事会 二〇二三年八 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-048 哈药集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 哈药集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 24 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了 解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 09 月 05 日下午 14:00-15:00 举行 2023 年半年度业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 09 月 05 日(星期二) 下午 14:00-15:00 会议召开地点： 上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-044 二、项目进展 本次被征收的标的房屋为公司非核心资产，已闲置多年， 协议的最终履行将有利于公司盘活资产，提高资产运营效率， 增加公司流动资金。根据《企业会计准则》等相关规定，公司 预期获得补偿款 123,264,303.91 元,已于 2022 年确认资产处 置收益，扣除相关税费后影响 2022 年度损益 90,790,944.04 元。本次收到的首期征收补偿款 31,051,438.58 元,对公司当 期损益无影响，具体会计处理及金额以年审会计师年度审计确 认后的结果为准。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性 承担法律责任。 一、交易概述 经哈药集团股份有限公司（以下简称"公司"）2022 年 12 月 6 日第九届董事会第三十二次会议审议，同意松北区人民政 府对本公司下属公司哈药集团三精制药有限公司所有的哈尔 滨市松北区前进乡金星村房屋进行征收，具体内容详见公司于 上海证券交易所网站（www.sse.com.cn）上披露的《哈药集团 股份有限公司九届三十二 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-036 哈药集团股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者 网上集体接待日活动暨 2022 年度业绩说明会的 公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 15 日(星期一)下午 14:00-16:30 会议召开地点："全景路演"网站（http://rs.p5w.net） 会议召开方式：网络远程方式 投资者可于 2023 年 5 月 10 日(星期三)至 5 月 12 日(星期五)16:00 前 将有关问题通过电子邮件的形式发送至公司邮箱：master@hayao.com。 公司将在信息披露允许的范围内对投资者普遍关注的问题进行回答。 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 下简称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与 深圳市全景网络有限公司联合举办的"2023 年黑龙江辖区上市公司 投资者集体接待日活动暨 2022 年度业绩说明会"，现将相关事项公 ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-036 哈药集团股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者 网上集体接待日活动暨 2022 年度业绩说明会的 公告 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 下简称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与 深圳市全景网络有限公司联合举办的"2023 年黑龙江辖区上市公司 投资者集体接待日活动暨 2022 年度业绩说明会"，现将相关事项公 告如下： 一、说明会类型 本次活动将采用网络远程的方式举行，投资者可就公司 2022 年 度业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 15 日下午 14:00-16:30 会议召开时间：2023 年 5 月 15 日(星期一)下午 14:00-16:30 会议召开地点："全景路演"网站（http://rs.p5w.net） 会议召开方式：网络远程方式 投资者可于 2023 年 5 月 10 日(星期三)至 5 月 12 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3,931,549,972.98, representing a year-on-year increase of 17.93%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 122,293,236.02, up 21.75% compared to the same period last year[4] - Basic earnings per share for Q1 2023 were CNY 0.05, an increase of 25.00% from the previous year[4] - Total operating revenue for Q1 2023 reached ¥3,931,549,972.98, a 17.9% increase from ¥3,333,837,987.01 in Q1 2022[16] - Net profit for Q1 2023 was ¥139,987,574.96, representing a 27.4% increase compared to ¥109,934,338.19 in Q1 2022[17] - Total comprehensive income for Q1 2023 was ¥141,147,470.62, compared to ¥110,203,928.60 in Q1 2022, reflecting a growth of 28.1%[18] Cash Flow - The net cash flow from operating activities was CNY 182,625,091.63, reflecting a 17.91% increase year-on-year[4] - Cash inflow from operating activities in Q1 2023 was ¥4,022,411,651.90, up 22.7% from ¥3,277,424,882.21 in Q1 2022[20] - Net cash flow from operating activities for Q1 2023 was 182,625,091.63, an increase from 154,882,854.26 in Q1 2022, representing a growth of approximately 17.5%[21] - Net cash flow from financing activities was 62,865,637.35, a significant improvement from -5,098,076.67 in Q1 2022[22] - The company reported a net increase in cash and cash equivalents of 231,223,678.32, compared to 161,605,207.78 in the same period last year, representing a growth of approximately 43.0%[22] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 13,540,956,681.83, a 0.78% increase from the end of the previous year[4] - The company's total assets amounted to RMB 13,540,956,681.83, an increase from RMB 13,435,980,913.62 as of December 31, 2022, reflecting a growth of approximately 0.78%[15] - The company's total liabilities were RMB 8,447,947,901.95, down from RMB 8,484,927,244.36, representing a decrease of about 0.44%[14] - The company’s total liabilities to equity ratio improved to approximately 1.67 from 1.71, indicating a stronger equity position relative to liabilities[14] Expenses - The company's R&D expenses increased by 34.49% year-on-year, attributed to the expansion of R&D projects[6] - The company reported a 44.87% increase in sales expenses, driven by higher investment in health product business due to increased revenue[6] - Total operating costs for Q1 2023 were ¥3,749,463,341.18, up 18.0% from ¥3,175,613,101.54 in Q1 2022[16] - The company reported a decrease in financial expenses to ¥8,332,222.00 in Q1 2023 from ¥28,262,561.51 in Q1 2022[16] Shareholder Equity - The company's equity attributable to shareholders increased to RMB 4,455,333,420.22 from RMB 4,331,072,648.54, reflecting a growth of approximately 2.86%[14] - The company completed the repurchase and cancellation of 2,399,000 restricted stocks as part of its stock incentive plan, reducing total shares from 2,525,877,076 to 2,523,478,076[9]